research Hair today, gone tomorrow
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
Search
for
Sort by
Research
900-930 / 1000+ results 
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
Sorafenib often causes skin side effects, indicating effective cancer treatment.
research A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
research Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2
Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Dermatological Manifestations of Pegylated Interferon alfa2a and Ribavirin Combination Therapy in Chronic HCV Patients
Most patients on this hepatitis C treatment experienced skin issues, especially hair loss.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research Finasteride and prostate cancer
Finasteride's effects on prostate cancer are not clear from this text.
research New 5?-reductase inhibitors: In vitro and in vivo effects
Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
Interferon and ribavirin can cause serious skin reactions and other health issues.
research MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
research Allopregnanolone promotes proliferation and differential gene expression in human glioblastoma cells
Allopregnanolone increases growth and changes gene activity in human brain cancer cells.
research Molecular Interactions of New Pregnenedione Derivatives
The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market
Biosimilars lower costs but don't significantly improve access.
research Severe Pustular Drug Eruptions From Amivantamab: A Case Series
Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
research Data from Synergistic Function of Smad4 and PTEN in Suppressing Forestomach Squamous Cell Carcinoma in the Mouse
Deleting Smad4 and PTEN genes in mice causes rapid, invasive stomach cancer.
research PD35-08 ASSOCIATION OF COMMON MEDICATION WITH PROSTATE-SPECIFIC ANTIGEN LEVEL IN 45-YEAR-OLD GERMAN MEN: RESULTS OF THE PROBASE TRIAL
Some common medications can lower PSA levels in 45-year-old German men.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells.
Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
research Successful Treatment of Coexisting Alopecia Areata and Bullous Pemphigoid With Dupilumab: A Case Report
Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
research Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone
Male hormones worsen kidney transplant damage, but blocking them helps.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
research Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance
The new nanoparticles could improve melanoma treatment by working better than current options.